- Conditions
- Acute Apical Abscess, Pain, Acute
- Interventions
- Valacyclovir 500 MG, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Otitis Media (AOM)
- Interventions
- Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Complicated Urinary Tract Infections or Pyelonephritis
- Interventions
- Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
- Conditions
- Sinus Infection, Acute Sinusitis
- Interventions
- amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
- Drug
- Lead sponsor
- Daniel Merenstein
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
- Conditions
- Acute Respiratory Infections, Acute Rhinosinusitis
- Interventions
- Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sinusitis, Respiratory Tract Infections
- Interventions
- Amoxicillin-clavulanate, Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Bardstown, Kentucky • Gresham, Oregon • Philadelphia, Pennsylvania + 3 more
- Conditions
- Functional Gastrointestinal Disorders
- Interventions
- Amoxicillin, Placebo
- Drug · Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
- Interventions
- Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
- Interventions
- Amoxicillin, Placebo
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Months to 71 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Pain, Postoperative
- Interventions
- Ibuprofen 600 mg, Local anesthetic Group 1, Placebo oral capsule, Local anesthetic Control
- Drug
- Lead sponsor
- Satheesh Elangovan
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Healthy
- Interventions
- Amoxicillin + MMX placebo, Amoxicillin + MMX mesalazine/mesalamine
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Helicobacter Pylori
- Interventions
- Bismuth quadruple therapy with optimized PPI, Bismuth quadruple therapy with standard PPI, Clarithromycin triple therapy with optimized PPI, Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Tonsillectomy
- Interventions
- 7 days of amoxicillin, 3 days of amoxcillin followed by 4 days of placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Vaginitis Gardnerella
- Interventions
- Amoxicillin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Winston-Salem, North Carolina